Tag: source

MONTRÉAL, 10 juin 2025 (GLOBE NEWSWIRE) -- Groupe Prime Drink Corp. (CSE : PRME) (« Prime » ou la « Société ») annonce la mise sous séquestre de sa filiale d’embouteillage, anciennement connue sous le nom de Triani Canada Inc. (« Triani »), et la cessation des activités de sa filiale. La mise sous séquestre de Triani a été ordonnée le 10 juin 2025 par la Cour supérieure, district de Montréal, à la demande des principaux créanciers de Triani en vertu de l'article 243 de la Loi sur la faillite et l'insolvabilité (Canada), tel que divulgué dans le communiqué de presse de la Société du 7 avril 2025.

MONTREAL, June 10, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that its bottling subsidiary, formerly known as Triani Canada Inc. (“Triani”), has been placed into receivership and has ceased operations. Triani’s receivership was ordered on June 10, 2025, by the Superior Court, District of Montreal, at the request of Triani's principal creditors pursuant to Section 243 of the Bankruptcy and Insolvency Act (Canada), as disclosed in the Company's press release dated April 7, 2025.

Trusted Telemedicine Platform for Medical Marijuana Expands Access Across 25+ States Where Legal

Updated Virtual Weight Loss Platform Expands Access to GLP-1 Support and Clinician-Guided Obesity Care Across All 50 States

EDMONTON, Alberta, June 10, 2025 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, announced today that Quest was not informed or consulted, opposes and will not support the recently announced acquisition by privately held South Korea-based OQPBIOM Inc. (“OQM”) of a controlling interest in AdBioTech Co., Ltd. (“AdBioTech”), a public company listed on KOSDAQ in South Korea. OQM has announced that AdBioTech is the corporate vehicle through which it wishes to pursue the funding and advancement of its immunotherapy assets.